BABurak Andaç

Burak Andaç

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Burak Andaç has a total of 134 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Framework-Dependent Classification and Long-Term Outcomes of Historical NIFTP: A Slide Re-Review with Follicular-Variant Papillary Thyroid Carcinoma Comparators

    by Buket Yılmaz Bulbul, Nuray Can, Nuri Isler, Burak Andac, Esra Zeynep Yucesan, Buse Ekici, Isil Yigitbasi, Seda Dogan, Gamze Nur Aktas, Mehmet Celik

    Background/Objectives: Diagnostic criteria for non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) have changed twice since 2016, most visibly in the tolerance for true papillae and in the role of molecular findings. We evaluated historical NIFTPs under the original and subsequent frameworks and related framework-specific classification to long-term outcomes. Methods: In this single-center, retrospective cohort (surgery 2007–2016), archival slides of 79 historical NIFTPs with linked longitudinal follow-up were independently re-reviewed in 2026 by two pathologists without knowledge of long-term outcomes or molecular results; their framework-specific classifications were concordant in all cases. Reasons for failure to retain the diagnosis across all frameworks were classified as criterion-dependent, criterion-independent, or technical. Outcomes were compared with 56 infiltrative and 39 invasive encapsulated follicular-variant papillary thyroid carcinomas (FVPTCs) from the same institution. Results: Thirty-six tumors (45.6%; 95% CI, 34.3–57.2%) qualified as NIFTP under all frameworks. Retention was 47/79 (59.5%; 95% CI, 47.9–70.4%) under the original 2016 criteria, 37/79 (46.8%; 95% CI, 35.5–58.4%) under the 2018 consensus primary criteria, and 46/79 (58.2%; 95% CI, 46.6–69.2%) under WHO 2022. Ten tumors with well-formed true papillae occupying <1% qualified under 2016 and WHO 2022 but not under the 2018 criteria. One additional BRAF V600E-positive tumor had no well-formed papillae, an entirely follicular growth pattern, and a nuclear score of 3; it fulfilled the 2016 and 2018 primary morphologic criteria but was excluded under WHO 2022 because BRAF V600E was detected. Criterion-independent discordance between the historical classification and contemporary re-review accounted for 28/79 tumors (35.4%; 95% CI, 25.0–47.0%). During a median follow-up of 132 months, no incident structural events were observed among historical NIFTPs (0/64; upper 95% CI, 5.6%), and none of 36 with examined lymph nodes had nodal metastasis, whereas nodal metastasis at surgery (4/27) and the only incident structural recurrence occurred among invasive encapsulated FVPTCs. Conclusions: Framework-specific retention ranged from 46.8% to 59.5%, driven mainly by the papilla criterion and, in one molecularly discordant case, BRAF V600E status. Most diagnostic loss reflected criterion-independent discordance identified on contemporary dual-pathologist slide re-review. No incident structural events were observed among outcome-evaluable historical NIFTPs during a median follow-up of 11 years.

  • Genetic spectrum and treatment implications of maturity-onset diabetes of the young in the eastern Black Sea region of Türkiye: a combined adult and pediatric cohort of 296 patients with identification of rare and novel variants

    by Çağrı Doğan, Burak Andaç, Mehtap Navdar Başaran, Yasemin Emür Günay, Mustafa Tarık Alay, Aysel Kalaycı

    Background Maturity-onset diabetes of the young (MODY) is a clinically and genetically heterogeneous group of monogenic diabetes subtypes that is frequently misdiagnosed as type 1 or type 2 diabetes, and accurate genetic diagnosis enables a precision-medicine treatment approach. Regional Turkish data are limited, and previous Turkish series have been pediatric only. We characterized the genetic spectrum and therapeutic consequences of next-generation sequencing (NGS)-based MODY testing in a combined adult-and-pediatric cohort from the eastern Black Sea region of Türkiye. Methods and results We retrospectively analyzed 296 consecutive patients with clinically suspected MODY referred between January 2022 and June 2025. A targeted NGS panel covering 14 MODY genes was applied, variants were classified per 2015 ACMG/AMP criteria, and treatment changes attributable to the genetic diagnosis were extracted from medical records. Pathogenic or likely pathogenic (P/LP) variants were identified in 43 of 296 patients (14.5%); diagnostic yield rose to 26.0% with variants of uncertain significance included. GCK-MODY accounted for 72.1% of P/LP findings, with a recurrent frameshift c.1256del p.(Phe419SerfsTer12) across nine apparently unrelated families consistent with a regional founder allele. Rare subtypes included MODY4 (PDX1), MODY6 (NEUROD1), MODY8 (CEL), MODY10 (INS), MODY12 (ABCC8) and MODY13 (KCNJ11). The genetic diagnosis directly modified pharmacological therapy in 14 patients, including insulin discontinuation in three KATP-channel MODY and one INS-MODY case. Conclusions NGS-based MODY testing yields actionable findings in approximately one in seven clinically selected patients in this region and supports inclusion of MODY testing in routine endocrinology practice.

  • Open Access

    Atherogenic Burden and Insulin Resistance in Non-Obese Women with Polycystic Ovary Syndrome: A Comparative Study with Healthy Controls

    by Burak Andaç, Mehtap Navdar Başaran, Gözde Nur Eren

    Objective: Polycystic ovary syndrome (PCOS) is associated with elevated cardiovascular disease (CVD) risk due to metabolic derangements. Although obesity contributes to CVD, the independent contribution of PCOS remains controversial. This study aimed to compare insulin resistance (IR) and atherogenic lipid indices across body mass index (BMI) categories within PCOS, to evaluate the diagnostic performance of atherogenic indices between non-obese PCOS and healthy controls, and to derive exploratory, data-driven thresholds that may inform cardiovascular risk assessment in non-obese PCOS. Methods: This single-center case-control study enrolled 65 treatment-naïve women newly diagnosed with PCOS (Rotterdam criteria 2003) and 100 age-matched healthy controls. A panel of IR and composite atherogenic lipid indices (e.g., Lipid Accumulation Product [LAP], Visceral Adiposity Index [VAI], Triglyceride-Glucose [TyG] Index) was compared between groups. Results: Within PCOS, atherogenic lipid indices were similar in obese versus non-obese subgroups. Non-obese PCOS demonstrated significantly higher atherogenic lipid and IR indices compared to controls (all P<0.05). Receiver operating characteristic (ROC) curve analysis identified LAP (Area under the curve [AUC] =0.747, 95% confidence intervals [CI]: 0.647-0.844, threshold=18.05), VAI (AUC=0.707, 95% CI: 0.605-0.811, threshold=1.15), and TyG (AUC=0.701, 95% CI: 0.583-0.814, threshold=8.29) as the three best indices distinguishing non-obese PCOS from healthy controls. Conclusion: Elevated atherogenic lipid and IR indices in non-obese PCOS compared to non-obese controls, alongside similar atherogenic markers between obese and non-obese PCOS groups are consistent with the notion that PCOS may independently contribute to atherogenesis beyond obesity-related mechanisms. In this exploratory analysis, data-driven thresholds for LAP, VAI and TyG were identified in non-obese PCOS. These values require external validation in larger, multi-center cohorts before they can be considered for routine CVD risk screening or monitoring.

  • Open Access

    The Relationship Between Serum MG53 Levels and the Presence of Metabolic Syndrome and Its Components

    by Serpil Yanık Çolak, Burak Andaç, Eray Özgün, Buket Yılmaz Bülbül, Mine Okur, Ali Cem Yekdeş, Çağla Yıldız, Mehmet Çelik

    Background and Objectives: MG53 is a myokine/cardiokine involved in membrane repair. Some preclinical studies suggest that it is associated with insulin resistance. Metabolic syndrome (MS) is manifested by dyslipidemia, hypertension (HT), visceral obesity, hyperinsulinism, and glucose intolerance. We aimed to evaluate the relationship between the MG53 protein and MS and its components. Materials and Methods: This study was conducted among 64 patients with MS and 64 age- and sex-matched healthy participants. MG53 levels were measured using Human-MG53, a commercially available enzyme-linked immunosorbent assay (ELISA) kit (Cat# CSB-EL024511HU, Alfagen laboratory supplies, Cusabio, Bornova, İzmir.). Results: There was no significant connection between serum MG53 levels and the presence of MS (p = 0.969). We found no correlation between serum MG53 levels and the presence of HT, weight, waist circumference, body mass index, HDL-C, fasting blood glucose, and HbA1c levels. Conclusions: This study’s results suggest no association between serum MG53 levels and MS parameters in the studied ethnic population. Due to the limited number and controversy of available studies on this subject, our findings may provide perspective for conducting studies with more diverse populations to obtain more comprehensive results.


  • Open Access

    The association between integrin β4 overexpression and lymphovascular invasion in papillary thyroid cancer

    by Busra Tunc Topuz, Sibel Guldiken, Ebru Tastekin, Canberk Topuz, Mehmet Celik, Buket Yılmaz Bulbul, Burak Andac, Ali Cem Yekdes

    Introduction: Lymphovascular invasion is an independent prognostic marker in papillary thyroid carcinomas. In addition, integrin β4 is associated with advanced progression and metastasis in many malignancies. We aimed to investigate the relationship between integrin β4 and lymphovascular invasion in papillary thyroid carcinoma. Material and methods: 73 patients with papillary thyroid cancer (48 patients with lymphovascular invasion and 25 patients without) were included in our study. The immunohistochemical staining score for integrin b4 was evaluated according to the percentage and intensity of staining. The staining intensity was scored as 0 (no staining), 1 (weak staining — light yellow), 2 (medium staining — yellow-brown), and 3 (strong staining — brown). The staining was scored by multiplying the percentage and intensity of staining. Results: The mean percentage of integrin b4 staining was 63.54 ± 22.26% in the group with lymphovascular invasion and 10.2 ± 22.48% in the group without lymphovascular invasion (p < 0.001). When evaluated in terms of staining score, it was found to be 107.08 ± 45.29 in the group with lymphovascular invasion and 16.2 ± 40.03 in the group without lymphovascular invasion (p < 0.001). There was a linear relationship between the percentage of integrin β4 and the staining scores (r² = 0.881; p < 0.001). In the by receiver-operating characteristic (ROC) curve analysis for the cut-off value of the percentage of integrin b4 staining, the area under the curve was found to be 0.916. The cut-off value for the percentage of integrin b4 was found to be 35 (sensitivity 91.7% and specificity 88%) (odds 80.66%). Conclusions: A significant relationship was found between integrin b4 expression and lymphovascular invasion in papillary thyroid carcinomas. Integrin b4 expression level can be used as a marker to predict the presence of lymphovascular invasion in papillary thyroid carcinomas, especially in large tumours where it may not be possible to sample the entire tumour. Keywords: thyroid cancer integrin β4 lymphovascular invasion


  • Overview of Clinical, Pathological and Treatment Features of the Patients with Endometrium Cancer: A Single Center Study

    by Burak Andaç, Sernaz Uzunoglu, Bulent Erdogan, Muhammet Bekir Hacioglu, Ali Cem Yekdeş, Cagla Yildiz, Irfan Çiçin

    Objectives: Endometrial cancer is the second most common gynecological cancer worldwide. Despite being usually diagnosed at an early stage with a better prognosis compared to other gynecological cancers, some cases can be aggressive. Obtaining data on independent prognostic factors correlated with survival and recurrence would be beneficial to control the disease and make informed systemic treatment decisions effectively. We aimed to review endometrial cancer's clinical and pathological features and determine the prognostic risk factors. Methods: We conducted a retrospective study on 136 individuals with endometrial cancer who were followed up between 1997 and 2015. Prognostic factors with a p-value of less than 0.15 using the Long-rank test were included in multivariate analysis. Multivariate analysis was performed by the Cox regression test. Results: Significant prognostic factors determining the overall survival in univariate analysis were disease stage, histological grade, age at diagnosis, histological type, lymph node metastasis, lymphatic and vascular invasion, depth of myometrial invasion, cervical stromal invasion, tumor diameter, the positivity of peritoneal cytology, and pre-op serum CA-125 levels. In multivariate analysis, advanced stage and high preoperative CA-125 levels were detected as factors reducing overall survival (p=0.012, p=0.005, respectively). Conclusion: The two most important factors for endometrial cancer survival were stage and pre-op serum CA-125 level, independent of other parameters. As our study was retrospectively done with a limited number of patients, more extensive prospective, randomized studies with a larger number of patients are necessary to apply the information obtained from this study to our clinical practices.

  • Falsely Elevated Thyroid Stimulating Hormone in Two Cases Requiring Special Follow-up

    by Serpil Yanik Çolak, Eray Özgün, Burak Andaç, Mine Okur, Buket Yilmaz Bülbül, Mehmet Çeli̇k

  • Open Access

    25-Hydroxyvitamin D Status In Type 1 Diabetic Adults And Its Relationship With Glycemic Control

    by Burak Andaç, Buket Yılmaz Bülbül, Mehmet Oğulcan Tezel, Mine Okur, Serpil Yanık Çolak, Buse Ekici, Mehmet Celik

    Objective: To assess the vitamin D levels between adults with type 1 diabetes mellitus and the healthy control group and evaluate the relationship between HbA1c levels and vitamin D status in the diabetic group. Methods: Our cross-sectional, descriptive study included 98 type 1 diabetic patients over 18 years old who applied to the Endocrinology Outpatient Clinic and 95 age- and sex-matched individuals without chronic disease. Patients with advanced renal or liver disorders, primary hyperparathyroidism, metabolic bone disorders, or using medications that might change vitamin D concentrations were excluded from the study. HbA1c and 25(OH) Vitamin-D3 levels were measured three times in 9 months, and the average of the measurements was used. Diabetic patients and control individuals were separated into three groups according to their vitamin D levels as follows: deficiency ( 20 ng/ml). Results: Serum 25 (OH) vitamin D levels of diabetic patients were significantly lower than in healthy individuals (p=0.024). However, when diabetic adults were separated into three groups according to 25(OH) vitamin D levels, there was no significant difference regarding HbA1c levels (p=0.905). Conclusion: Although preclinical data support the role of low serum vitamin D levels in the etiopathogenesis of type 1 diabetes mellitus, studies examining the connection between low serum vitamin D levels and the prevalence of type 1 diabetes or glycemic control are not sufficient to reach a clear conclusion, including our study.

  • Open Access

    Assessment of three different radioiodine doses for ablation therapy of thyroid remnants: Efficiency, complications and patient comfort

    by Selin Soyluoglu, Burak Andac, Ulku Korkmaz, Funda Ustun

    I-131 radioiodine (RAI) ablation removes postoperative residual tissue and facilitates follow-up in low- and intermediate-risk differentiated thyroid cancer (DTC). Although low doses have been reported to be as effective as higher doses for ablation, the doses administered still vary depending on the patient and the practitioner. We aimed to evaluate the ablation efficiency, complications, and length of stay (LOS) of patients with DTC treated with 3 different doses for ablation. Patients with DTC who received RAI therapy were retrospectively reviewed. One hundred thirty patients with low-intermediate-risk, according to American Thyroid Association classification, without known lymph nodes or distant metastases were included. Patients were divided into 3 groups as 30 to 50 mCi, 75 mCi, and 100 mCi. Residue thyroid and salivary glands were evaluated from 9 to 12 months post-RAI I-131 scans. No significant difference was found between groups regarding ablation success (P = .795). In multivariable analyses, pretreatment thyroglobulin (hazard ratio = 0.8, 95% confidence interval 0.601–0.952, P = .017) and anti- thyroglobulin antibody (hazard ratio = 1.0, 95% confidence interval 0.967–0.998, P = .024) were 2 independent predictors of ablation success. The mean LOS was 2.1 ± 0.3, 2.6 ± 0.6, and 2.9 ± 0.4 days, respectively, (P = .001). LOS rates of ≥ 3 days were 13.2%, 54.3%, and 84.8%, respectively. Mild decreases in hemoglobin, white blood cell (WBC), and platelet counts were observed in all groups after 6 weeks without any clinically significant findings. A lower rate of change in WBC counts was observed in the 30 to 50 mCi group compared to others. There was no dose-dependent difference regarding the early complaints questioned. Ablation with 30 to 50 mCi provides benefits such as shorter LOS, better patient comfort, less salivary gland dysfunction, and less WBC suppression, thus reducing costs without decreasing efficacy.


  • Open Access

    Association of MG53 with presence of type 2 diabetes mellitus, glycemic control, and diabetic complications

    by Burak Andaç, Eray Özgün, Buket Yılmaz Bülbül, Serpil Yanık Çolak, Mine Okur, Ali Cem Yekdeş, Eftal Öcal, Mehmet Emin Tapan, Mehmet Çelik

    Objectives: Mitsugumin 53 (MG53) is a myokine that acts as a membrane repair protein in tissues. Data on the effect of MG53 on insulin signaling and type 2 diabetes mellitus (T2 DM) are still unknown; most are from preclinical studies. Nevertheless, some researchers have argued that it may be a new pathogenic factor, and therapies targeting MG53 may be a new avenue for T2 DM. Our study aims to evaluate the relationship of circulating MG53 levels with the presence of diabetes, diabetic complications, and glycemic control. Methods: We conducted a case-control study with 107 patients with T2 DM and 105 subjects without insulin resistance-related disease. Concurrent blood samples were used for serum MG53 levels and other biochemical laboratory data. MG53 concentration was measured using Human-MG53, an enzyme-linked immunosorbent assay kit (Cat# CSB-EL024511HU). Results: We found no difference in MG53 levels between the diabetic and control groups (p = 0.914). Furthermore, when the subjects were divided into tertiles according to their MG53 levels, we did not find any difference between the groups in terms of the presence of diabetes (p = 0.981). Additionally, no correlation was observed between weight, BMI, waist circumference, systolic and diastolic blood pressure, fasting blood glucose, HbA1c, albumin excretion in the urine, e-GFR levels, and MG53. Finally, MG53 levels were similar between the groups with and without microvascular and macrovascular complications of diabetes. Conclusion: Our research finding provides insightful clinical evidence of lack of association between the levels of MG53 and T2 DM or glycemic control, at least in the studied population of Turkeys ethnicity. However, further clinical studies are warranted to establish solid evidence of the link between MG53, insulin resistance and glycemic control in a wider population elsewhere in the world.